病态和功能性大脑粉样蛋白:一种新的概念解释了差异
Alexey P Galkin1,2, Vladimir A Mitkevich3, Alexander A Makarov3
1St. Petersburg Branch, Vavilov Institute of General Genetics, Russian Academy of Sciences, 199034 St. Petersburg, Russia.
International journal of molecular sciences
|November 13, 2025
概括
根据它们的组成,大脑粉样蛋白质本质上不是有毒的. 相反,它们的毒性取决于与特定细胞点的相互作用,区分有害和功能性粉样蛋白.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 大脑中的粉样蛋白可能是功能性或神经毒性.
- 大脑粉样蛋白的不同作用背后的原因尚不清楚.
- 以前的假设表明氨基酸组成决定了粉样蛋白毒性.
研究的目的:
- 为了比较病理和功能性脑粉样蛋白的氨基酸组成.
- 调查决定粉样蛋白神经毒性的因素.
- 探索"可用标"在粉样蛋白病原体的概念.
主要方法:
- 对大脑粉样蛋白的氨基酸序列进行比较分析.
- 对粉样蛋白与细胞点相互作用的现有证据的审查.
- 检查影响功能性粉样蛋白目标可达性的因素.
主要成果:
- 病理和功能性大脑粉样蛋白及其碎片在氨基酸组成上没有显著差异.
- 氨基酸毒性不仅仅是由于氨基酸序列,而是受到与特定点的相互作用的影响.
- 功能性粉样蛋白因细胞局部化或生理结合而免受毒性相互作用的保护.
结论:
- 氨基酸成分不区分有毒与无毒的大脑粉样蛋白.
- 粉样蛋白毒性源于与可访问的细胞点的异常相互作用.
- 功能性粉样蛋白通过分隔或生理相互作用避免毒性,使目标无法获得.
关键词:
氨基胺基核的核心.氨基酸是功能性合作伙伴.大脑大脑大脑的大脑大脑细胞局部化 细胞局部化进行比较分析.功能性与病理性粉样蛋白相比.神经退行性疾病的神经退行性疾病神经毒性的作用.病理目标是病理目标.蛋白质的错误折叠 蛋白质的错误折叠更多相关视频
相关概念视频
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Amyloid Fibrils
6.3K
6.3K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


